CEP + dasatinib + azacitidine

CEP + dasatinib + azacitidine is an investigational combination therapy comprised of three components: CEP (identity not specifically defined in the available search results), dasatinib (a multi-kinase inhibitor that targets BCR-ABL, KIT, SRC family kinases, among others), and azacitidine (a hypomethylating agent that incorporates into DNA and RNA, inhibiting DNA methyltransferases and promoting DNA hypomethylation and cytotoxicity in abnormal hematopoietic cells). This regimen is being studied as a first-line treatment for angioimmunoblastic T-cell lymphoma and potentially other hematological malignancies. Dasatinib blocks signaling pathways critical for leukemic cell survival and proliferation, while azacitidine modulates gene expression through epigenetic reprogramming. The combination may be intended to target multiple leukemic subclones and cellular pathways to overcome resistance and improve therapeutic outcomes[3]. The specific mode of action and role of CEP in this combination is not detailed in the search results; however, it is likely another chemotherapeutic or targeted agent, given the context of combination regimens for aggressive hematologic cancers.